September 29 is World Heart Day. For the past six decades, Novartis has been working to advance heart health around the world.

AI offers the greatest potential to transform health systems from being reactive to proactive, predictive, and even preventive.

European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Novartis Chief Digital Officer, Bertrand Bodson, and Microsoft Corporate Vice President Research & Incubation, Peter Lee, discussed why healthcare’s digital moment is now.

The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.

NIBR translational immunologists and academic colleagues observe two distinct molecular patterns of disease progression in lung tissue samples.

To celebrate International Women’s Day we explore how an inclusive environment that values unique and curious minds helps everyone be inspired to innovate every day.

Individualized CAR‑T therapy uses a patient’s own immune system to fight certain types of cancers.

Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.